Related references
Note: Only part of the references are listed.Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
C. Pawlyn et al.
BLOOD CANCER JOURNAL (2017)
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition
Ola Rizq et al.
CLINICAL CANCER RESEARCH (2017)
EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes
Henar Hernando et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors
M. Wassef et al.
CELL CYCLE (2016)
A double-negative feedback loop between EZH2 and miR-26a regulates tumor cell growth in hepatocellular carcinoma
Chunbo Zhuang et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
EZH2 is associated with poor prognosis in head-and-neck squamous cell carcinoma via regulating the epithelial-to-mesenchymal transition and chemosensitivity
Jae Won Chang et al.
ORAL ONCOLOGY (2016)
RRx-001: A double action systemically non-toxic epigenetic agent for cancer therapy
Hongjuan Zhao et al.
CANCER RESEARCH (2015)
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma
Y. Yang et al.
LEUKEMIA (2015)
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Noah M. Merin et al.
PHARMACEUTICALS (2015)
Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
M. N. Saha et al.
BRITISH JOURNAL OF CANCER (2014)
c-Myc-Mediated Epigenetic Silencing of MicroRNA-101 Contributes to Dysregulation of Multiple Pathways in Hepatocellular Carcinoma
Lei Wang et al.
HEPATOLOGY (2014)
MicroRNA theragnostics for the clinical management of multiple myeloma
N. Ahmad et al.
LEUKEMIA (2014)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Clinical Applications for microRNAs in Cancer
S. P. Nana-Sinkam et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Functional characteristics of a double negative feedback loop mediated by microRNAs
Shuiming Cai et al.
COGNITIVE NEURODYNAMICS (2013)
Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication
Irena Misiewicz-Krzeminska et al.
HAEMATOLOGICA (2013)
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms
Jahangir Abdi et al.
ONCOTARGET (2013)
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence
Maria T. Di Martino et al.
CLINICAL CANCER RESEARCH (2012)
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
P. Tagliaferri et al.
CURRENT CANCER DRUG TARGETS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1
Yi-Kun Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Systemic Delivery of Tumor Suppressor microRNA Mimics Using a Neutral Lipid Emulsion Inhibits Lung Tumors in Mice
Phong Trang et al.
MOLECULAR THERAPY (2011)
Polycomb Target Genes Are Silenced in Multiple Myeloma
Antonia Kalushkova et al.
PLOS ONE (2010)
The Putative Tumor Suppressor microRNA-101 Modulates the Cancer Epigenome by Repressing the Polycomb Group Protein EZH2
Jeffrey M. Friedman et al.
CANCER RESEARCH (2009)
MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer
Ming Shi et al.
CANCER TREATMENT REVIEWS (2009)
CDK2 Phosphorylation of Smad2 Disrupts TGF-β Transcriptional Regulation in Resistant Primary Bone Marrow Myeloma Cells
Linda B. Baughn et al.
JOURNAL OF IMMUNOLOGY (2009)
MicroRNAs in normal and malignant hematopoiesis
Ramiro Garzon et al.
CURRENT OPINION IN HEMATOLOGY (2008)
Potential therapeutic applications of miRNA-based technology in hematological malignancies
Elisa Barbarotto et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia
Ken I. Mills
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
MicroRNA in Acute Myeloid Leukemia
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
miRDB: A microRNA target prediction and functional annotation database with a wiki interface
Xiaowei Wang
RNA (2008)
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Sooryanarayana Varambally et al.
SCIENCE (2008)
Prediction of both conserved and nonconserved microRNA targets in animals
Xiaowei Wang et al.
BIOINFORMATICS (2008)
The microRNA.org resource: targets and expression
Doron Betel et al.
NUCLEIC ACIDS RESEARCH (2008)
Potentiation of Smad-mediated transcriptional activation by the RNA-binding protein RBPMS
Yan Sun et al.
NUCLEIC ACIDS RESEARCH (2006)
Oncomirs - microRNAs with a role in cancer
A Esquela-Kerscher et al.
NATURE REVIEWS CANCER (2006)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation
S Bagga et al.
CELL (2005)
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341
R Buzzeo et al.
CLINICAL CANCER RESEARCH (2005)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Share Paper
